Floatz logo

PIMITESPIB

Retinoblastoma Deficiency

Brown UniversitySmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Retinoblastoma Deficiency cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Itraconazole
Samsung Medical Center
Phase 4BB
Thiotepa
Masonic Cancer Center, University of Minnesota
Phase 2BB
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 2BB
Cyclophosphamide
Seattle Children's Hospital
Phase 2BB

View all 28 →

Same molecule, other indications

PIMITESPIB is also rated in:

Advanced or Metastatic Solid TumorDormant
CC
Indicative ·
43 / 100
View asset →
alveolar soft part sarcomaDormant
CC
Indicative ·
43 / 100
View asset →
refractory malignant neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →